For the year ending 2025-12-31, SLNCF had -$110,248K decrease in cash & cash equivalents over the period. -$62,326K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss after tax | -88,612 |
| Depreciation expense | 312 |
| Amortization expense | 243 |
| Share-based compensation expense | 8,074 |
| Net foreign exchange impacts | -11,022 |
| Other income, net | 3,480 |
| Income tax expense | 11 |
| Decrease/(increase) in trade receivables | -1,024 |
| Decrease/(increase) in other current assets | -6,016 |
| Decrease/(increase) in r&d benefit receivable | -4,041 |
| Decrease in other long-term assets | -3,658 |
| (decrease)/increase in trade and other payables | -4,078 |
| Decrease in contract liabilities | -334 |
| Decrease in operating lease liabilities | -168 |
| Net cash used in operating activities | -62,271 |
| Redemption of term deposits | 118,476 |
| Purchase of term deposits | 166,413 |
| Purchase of property, plant and equipment | 55 |
| Net cash used in investing activities | -47,992 |
| Proceeds from issue of ordinary shares | 15 |
| Net cash provided by financing activities | 15 |
| (decrease)/increase in cash and cash equivalents | -110,248 |
| Cash and cash equivalents at start of period | 121,330 |
| Effect of exchange rate fluctuations on cash and cash equivalents held | 195 |
| Cash and cash equivalents, end of period | 11,277 |
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)